Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Metagenomi reported second quarter financial results, ending the period with $120.7 million in cash and marketable securities, which the company anticipates will fund operations into the fourth quarter of 2027. The company confirmed it remains on track to submit an IND application for its lead hemophilia A program, MGX-001, in the fourth quarter of 2026, with IND-enabling studies expected to wrap up by the end of the third quarter.
Key figures
- Runway
- 4Q 2027
- Ga expenses
- 6004000
- Rd expenses
- 22512000
- Cash position
- 120700000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.